Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Humoral Immune Responses01:36

Humoral Immune Responses

72.5K
Overview
72.5K
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

84
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
84
Disorders of Leukocytes01:27

Disorders of Leukocytes

938
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
938
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.8K
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels01:31

Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels

210
Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
210

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Safe Environment for Every Kid (SEEK) Approach: Two Training Modalities and Child Maltreatment Prevention.

Academic pediatrics·2026
Same author

Clinical utility of a multianalyte lupus risk score incorporating cell-bound complement activation products: a systematic evaluation.

Lupus science & medicine·2026
Same author

Serum proteomic atlas reveals distinct molecular signatures of lupus nephritis activity, chronicity, and treatment response.

bioRxiv : the preprint server for biology·2026
Same author

"More guidelines than rules": reconsidering key gaps in the 2025 American College of Rheumatology treatment recommendations for systemic lupus erythematosus: comment on the article by Sammaritano et al.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

A systematic review and meta-analysis of axillary intra-aortic balloon pump as a bridge to advanced heart failure therapy.

Frontiers in cardiovascular medicine·2026
Same author

Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis.

Arthritis care & research·2026
Same journal

Associations Between Social Risk Factors and Acute Care Use Among Patients with Rheumatic Conditions.

Arthritis care & research·2026
Same journal

Engagement Patterns with an AI Health Coach for Systemic Sclerosis Self-Management: A Mixed Methods Study.

Arthritis care & research·2026
Same journal

Anorectal Dysfunction in Systemic Sclerosis: Clinical Phenotypes and Functional Patterns.

Arthritis care & research·2026
Same journal

Determinants of body mass index in early systemic sclerosis: implications for nutritional risk stratification.

Arthritis care & research·2026
Same journal

Frailty Predicts Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis.

Arthritis care & research·2026
Same journal

Assessing Reliability of an Electronic Gout Flare Assessment Protocol.

Arthritis care & research·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2025

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.2K

Hydroxychloroquine Improves Low Complement Levels.

Rebecca Jacobson1, Daniel Goldman2, Andrea Fava2

  • 1University of California, Irvine.

Arthritis Care & Research
|June 4, 2024
PubMed
Summary
This summary is machine-generated.

Starting hydroxychloroquine (HCQ) and maintaining higher HCQ blood levels significantly improves complement levels, particularly C4, in patients with systemic lupus erythematosus (SLE). This suggests HCQ may mitigate SLE progression by modulating complement consumption.

More Related Videos

Measuring the 50% Haemolytic Complement CH50 Activity of Serum
08:26

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

37.8K
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.6K

Related Experiment Videos

Last Updated: Jun 24, 2025

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.2K
Measuring the 50% Haemolytic Complement CH50 Activity of Serum
08:26

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

37.8K
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.6K

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Low complement levels are linked to systemic lupus erythematosus (SLE) disease activity and organ damage.
  • Understanding factors influencing complement levels is crucial for managing SLE outcomes.

Purpose of the Study:

  • To investigate the association between hydroxychloroquine (HCQ) whole blood levels and changes in complement levels in SLE patients.
  • To determine if initiating HCQ therapy impacts complement levels.

Main Methods:

  • Two analyses were conducted on prospectively collected SLE cohort data.
  • Comparison of complement level changes between patients starting HCQ and those not starting it.
  • Conditional logistic regression to assess the association between HCQ blood levels and complement levels across all visits.

Main Results:

  • Patients initiating HCQ showed significantly higher C4 normalization rates (40% vs. 13%) and greater increases in C3 and C4 levels compared to non-starters.
  • Higher HCQ whole blood levels correlated with an increased probability of normal C4 levels (OR 1.8-2.6).
  • The association was most pronounced at HCQ blood levels of 200 ng/mL or higher.

Conclusions:

  • Initiating HCQ and achieving higher HCQ blood levels are associated with significant improvements in complement levels, especially C4.
  • HCQ may prevent adverse SLE outcomes by influencing pathogenic mechanisms of complement consumption.
  • Therapeutic drug monitoring of HCQ levels may be beneficial for optimizing complement restoration in SLE.